Thalidomide, semen distribution, teratogenicity... and cost [7]

British Journal of Dermatology

Volumn 154, Issue 3, 2006, Pages 563-

  Laffitte, E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; THALIDOMIDE; DERMATOLOGICAL AGENT; TERATOGENIC AGENT;

BIRTH CONTROL; BIRTH DEFECT; BREEDING; CONDOM; CONGENITAL MALFORMATION; CONTRACEPTION; EMBRYOPATHY; EMBRYOTOXICITY; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HUMAN; LETTER; NEUROTOXICITY; NONHUMAN; PREGNANCY TEST; PREGNANT WOMAN; PRIORITY JOURNAL; SEMINAL PLASMA; SPERM; SPERM DONOR; SPERMATOGENESIS; SPERMATOZOON; TERATOGENICITY; DRUG COST; ENVIRONMENTAL EXPOSURE; MALE; METABOLISM; NOTE;

DERMATOLOGIC AGENTS; DRUG COSTS; HUMANS; MALE; PATERNAL EXPOSURE; SEMEN; TERATOGENS; THALIDOMIDE;

EID: 33644924056     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.07083.x     Document Type: Letter

References (8)

1. Wu JJ Huang DB Pang KR et al. Thalidomide: dermatological indications, mechanisms of action and side-effects Br J Dermatol 2005 153 254 73
2. Lutwak-Mann C Schmid K Keberle H Thalidomide in rabbit semen Nature 1967 214 1018 20
3. Teo SK Harden JL Burke AB et al. Thalidomide is distributed into human semen after oral dosing Drug Metab Dispos 2001 29 1355 7
4. Laffitte E Revuz J Thalidomide: an old drug with new clinical applications Expert Opin Drug Saf 2004 3 47 56
5. Lammer EJ Chen DT Hoar RM et al. Retinoic acid embryopathy N Engl J Med 1985 313 837 41
6. Brinker A Kornegay C Nourjah P Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program Arch Dermatol 2005 141 563 9
7. http://www.fda.gov/cder/drug/advisory/isotretinoin2005.htm
8. Castilla EE Ashton-Prolla P Barreda-Mejia E et al. Thalidomide, a current teratogen in South America Teratology 1996 54 273 7